GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

GLP-1 medications such as Wegovy, Mounjaro and Ozempic helped drive a 9% year-over-year increase in U.S. prescription dispensing revenue, which reached $683 billion in 2024.  A separate report found ...

Gut‑hormone incretins (e.g., GLP‑1 agonists) are the fastest growing segment, forecast to expand at a 33.15% CAGR through ...

A new obesity drug combining four hormones may outperform Wegovy and Mounjaro. Learn what it means for health, science, and investors.

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock lately despite its ...

A federal judge in Texas has upheld the FDA’s decision to remove GLP-1 drugs, including Novo Nordisk’s Ozempic and Wegovy, from its drug shortage list, rejecting a bid by compounding pharmacies to ...

More than a dozen lawsuits filed in New York and New Jersey claim that weight-loss drugs like Wegovy and Ozempic caused ...

LLY's $1.3 billion Verve deal marks its third M&A in 2025 as it pushes to diversify across cardiovascular, neuro and cancer ...

Ozempic is an FDA-approved medication for people with type 2 diabetes. It’s often prescribed off-label for weight loss — that ...

Hims & Hers (HIMS) defends recovery with personalized healthcare adoption, GLP-1 partnerships, and profit growth. Click here ...

Novo Nordisk, the Danish pharma company behind Ozempic, made a very dumb decision a few years ago that will massively eat ...

In the battle for weight-loss supremacy, Hims & Hers Health has emerged as a dark horse candidate shaking up the market.